On October 23, the Coalition to Advance Maternal Therapeutics (CAMT) convened its annual all-member meeting. This gathering brought together experts, advocates, and stakeholders dedicated to enhancing maternal health through improved therapeutic research and regulatory frameworks. The meeting featured special presentations by Dr. Camille Fabiyi from the National Institute of Child Read more…
Despite there being more than 3.5 million births in the United States each year, pregnant and lactating populations have been underrepresented in research, leading to limited data in the pregnancy section of drugs approved by the U.S. Food and Drug Administration (FDA) and to women, their families, and health care Read more…
By: Leah Golbert, SWHR Communications Intern On July 25, 2024, members of the Coalition to Advance Maternal Therapeutics (CAMT) convened to discuss updates on advancements in the inclusion of pregnant and lactating populations in clinical research. CAMT advocated for several federal appropriations requests for FY2024 and FY2025, which were the Read more…
By: Stacey Friedman, Center Road Solutions The Coalition to Advance Maternal Therapeutics (CAMT) hosted its annual all-member meeting on October 23, 2023 in Washington, D.C. The meeting brought together CAMT’s membership of advocates, policy professionals, and other stakeholders spanning diverse organizations, all of whom are dedicated to improving access to Read more…
During the recent national webinar and congressional briefing, “PRGLAC Then and Now: Where We Are and Where We’re Going,” the last of a three-part congressional briefing series hosted by the Coalition to Advance Maternal Therapeutics (CAMT), invited representatives from key federal agencies to discuss how they were working to advance Read more…
Experts agree that leaving pregnant and lactating populations out of clinical trials can cause harm and create uncertainty for both mother and baby. During the national webinar and congressional briefing, “Pregnant and Lactating Populations in Research: How Leaving These Populations Out Leaves Them Behind,” part two of a three-part series Read more…
While Congress and the Administration had several priorities toward the end of the 117th Congress, including passing an end-of-year spending package for fiscal year 2023, the Coalition to Advance Maternal Therapeutics (CAMT) was successful in its efforts to help drive policy toward greater inclusion of pregnant and lactating populations in Read more…
Including pregnant and lactating populations in research is critical to gaining a greater understanding of the safety and efficacy of medications on these populations and improve outcomes for both mother and baby. However, women of childbearing age have historically been excluded from clinical trials. In 1977, as a result of Read more…
Representatives Castor, Fitzpatrick, and Underwood on December 13, 2022 introduced H.R. 9487, the Advancing Safe Medications for Moms and Babies Act of 2022.